Arrests, detentions and deportations have been standard practice in every presidential administration. But President Donald Trump is looking to up the ante, allowing Immigration and Customs Enforcement (ICE) to conduct raids in more places and expanding where expedited removals can take place.

A student in the middle of the night darts downstairs from their dorm room in the Tonopah Residence Complex at UNLV to a brightly shining vending machine stationed in the building’s lobby.

Three days after Donald Trump became president, Immigration and Customs Enforcement (ICE) raided the Ocean Seafood Gourmet Market and Depot in Newark’s Ironbound district. ICE interrogated workers, including an American citizen, before making three arrests. It is not clear whether the agents had a judicial warrant. The raid helped launch the Trump administration’s long-promised blitzkrieg of immigration enforcement. Cabinet officials and TV cameras have accompanied ICE on other raids; publicity creates deterrence and reinforces MAGA messaging.

President Donald Trump’s tariff policy has, so far, been stop-and-go. Earlier this month, he announced a 25 percent import tariff on Canada and Mexico, then paused it for a month. He’s added new duties to the import of steel and aluminum, expanded tariffs on China and plans to pursue reciprocal tariffs across a host of nations and industries.

In December 2020, Ben Strahan thought he’d lost the will to live. It had been a long, isolating year for the Reno-based wildland firefighter. The COVID pandemic was still in full swing, and that year’s fire season had been extreme.

In December 2020, Ben Strahan thought he’d lost the will to live. It had been a long, isolating year for the Reno-based wildland firefighter. The COVID pandemic was still in full swing, and that year’s fire season had been extreme.

The newer class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic®) or tirzepatide (Mounjaro®, Zepbound®) are gaining popularity all over the world. It is reported that already 2-3% of Americans are taking these drugs. J.P. Morgan Research projects that by 2030, approximately 30 million people, or 9% of the U.S. population may be taking GLP-1 agonists.

Hoping that you can just file for bankruptcy and wipe out that debt ignores the fact that the court will be looking at your pre-bankruptcy behavior to see if you are eligible for a discharge of some or all of your debts.